{"name":"Orphelia Pharma","slug":"orphelia-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQdGZEZkxSSUtLdDQwZENseFRvQzdtcE9aenlMVFpoaVhDMjE2V0toYkUyOFhReEpKb2JSakJJMmI0dmc0Y2tJczFzcGF4WUhfeWRfZ2E3ay1SOHJpU2RpZ05ScmcxMENVc3pGQ3ZLMUtRUTRwbE1RR0EwTXZsSy1aM0c4cnR0VzV0TmdzZGVWUWxVRXM2MVg1VUY3ZmZUdDBaZDFVX2dxSkQ0by1kNkdkSnpyN05WUzJzVlJFVWhOSUhzWUp1Vmg4R2dxcUtQRXQ4VklnM0RYYng2ajNJSnNRR2xlZ1VWc19TQ2l5U3JJbnhiMW8?oc=5","date":"2025-12-15","type":"deal","source":"Investors in Healthcare","summary":"France: Orphalan acquires Orphelia Pharma to strengthen global commercial footprint in rare diseases - Investors in Healthcare","headline":"France: Orphalan acquires Orphelia Pharma to strengthen global commercial footprint in rare diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQNW9pMWlCRG1nYW01cndnS04xdXVCNEF2S3BRcjEycE1XdU5ZbEJ3NHh3a2ROZnpFQXA4aXY5N0NsRFRtNVpyekVRdFBlc2MzSmFlbzRxSWFwaHFORHVFUHBNRWxlMVNfbGRRQWNUVGsxYWlqeUVBTlBtNXpXQTd5M1FMWU12ZGkyMy03RmRUbWdtblhfV25oRWJUR2tVM1F0MklF?oc=5","date":"2025-03-12","type":"pipeline","source":"PharmaTimes","summary":"Orphelia Pharma explores other pathways for paediatric cancer treatment - PharmaTimes","headline":"Orphelia Pharma explores other pathways for paediatric cancer treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPVzZmUXcwcE81YUY5YlhkUjRPbjUyU1pucnJpaW1ZcGNTQThkcnpTSDZTenktc2lJamJUUnlOTFRGS0RvTUNyMmRuQUNPa0hNODQzaU02OUpDaUxDYkYzTUx0QWR3dE5LZWp0S3IxX2o1c1J6N1JqU3VWVVpxZXpQRGFRLTY0WGtsQmxjaUxXdkU5ZXR3em9iLXJGaUcxQUgtVEFfUEIzM3hUMmVXWXYzaV8tQkZ1Qm10R2dYOXZkaFgzMWdw?oc=5","date":"2025-03-12","type":"pipeline","source":"Pharmaceutical Technology","summary":"Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection - Pharmaceutical Technology","headline":"Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxObzVhTnBSMjViTFhxRk9SYlB2TExWc0RZNVJ5cDFQZW1KY2NtU2lhMUhYVndHZXU4NjBESS1zN0hRYks1bF9KTllBTkh0ZVY5NUNvVlFwVTZ2TXdRY3ZlTXlFRFNFYUV5R1pLLTFDWGhjR09TdWZyVnpXdXdiemR4cVNXeVZYUlNscUVFcVoyLXhMY0hNX2Fxb0s4S1ZnSE1GclBWandpVFFLTTFLSXBsLV9xVFFxU3F4LVRaUHhueER2WEpBN3A5Z3pNT180eEhpbTdFWmpSNA?oc=5","date":"2025-03-07","type":"pipeline","source":"PR Newswire","summary":"Orphalan becomes the first European company to enter in China's Wilson Disease market - PR Newswire","headline":"Orphalan becomes the first European company to enter in China's Wilson Disease market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPMG1tRFFoMUFDcWxTT3BpMm5YNkc3NUdOOE5FLVdQcDh3RndLVzRWUjd5N1kzM09OM01qQ0lWM1loZzFJdVVMX2NlWHY1V3drV0dxWVV6NVN5b0J4bVREelEtYWxHcHo1UjZZaGFBNE5HYVFxdTF6RVVHa090RlpIUVNjSmxPWWE0amswMlJSRkEyQnIw?oc=5","date":"2025-03-01","type":"regulatory","source":"The Pharma Letter","summary":"Three novel medicines recommended for approval by EMA/CHMP - The Pharma Letter","headline":"Three novel medicines recommended for approval by EMA/CHMP","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPWVRLVXI4Y3ItWTExUUFEYXcweFBmd1hRNnlWUDg0VDRQQmp5SWZqRkJXaUluS1hMVGVBRkx0RzR0X3dlZFl6Q0dVQTAwblJCTjBTNExVRV8xMmowRGdTelA4dm91Z1NGdGNPZHRDQ1AtMUhXWDBhdlg4R0l6SnN4NmxGMkxRYVRfVEpuR0MwX0dzTTlabWd3WDZCRnpvNkJlR0kzQXIwY001QkJ1M2ZoQW1oRmpoOFFnMWRJVEdTd3laZEJIZ1NXeHAyT2lid0JQMlozQU5OSS1USmxKQlpsTWcyRzhaQWRQRXJXUUk3Qi1hMzY1RjNpeG9Femd4RUJQbGJxdVpaMjM3OFFh?oc=5","date":"2023-04-18","type":"pipeline","source":"businesswire.com","summary":"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO® (temozolomide) in European Countries - businesswire.com","headline":"ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO® (temozolomide) in European Cou","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNYV92Z19iUUxxSEZOU1l0NkhxMTh3TXo1Z3ViVWxWdksxLUZwVTdDZVhmWTdyMm1xNjRlYmpBTGg3LUtZNklsMm9nNDZkTlFFbUt4SVh5TE9mcGF3UC0zWFpQaDJpcnloRl91Nmc3UE5SMDB4dlJJVFZNN1BPWm1sMURCaDRkTjlyOVFBd3lvc1p6aF9sdlJzRlVlcVBVcThuYUdFQUhPTmlHRWNpTm5LQ1JEM2lCTEJYV2JzMVhjV0FZZmN6Tnc?oc=5","date":"2022-06-09","type":"pipeline","source":"gustaveroussy.fr","summary":"ORPHELIA Pharma and Gustave Roussy announce the publication in Pharmaceuticals of the scientific work related to the development of the first temozolomide oral suspension for children - gustaveroussy.","headline":"ORPHELIA Pharma and Gustave Roussy announce the publication in Pharmaceuticals of the scientific work related to the dev","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQeVF3Rl9EOE9lTDFTcV9sRWVtSWFhZUk4ZHhEb3BqVFpIRmZUbVRoV09zVXdFQjl1NXFoc3huSzdDUDh3NG1RNW1DbkVxQ1Nhbm5zaWl4S19TVDV3TWhYbzNIQ203c3hmQWJwdnpMYm93LUEwZXRudDJrb2gxSTJtb21tNElsQTExY1BRN25pNVNxN2UyZkNTaEl6b05hMTExMERZUmZKX2h1LXNnQ1R3OG10ZjZyazBo?oc=5","date":"2021-06-16","type":"patent","source":"gustaveroussy.fr","summary":"ORPHELIA Pharma and Gustave Roussy announce issuance of European Patent covering Kimozo - gustaveroussy.fr","headline":"ORPHELIA Pharma and Gustave Roussy announce issuance of European Patent covering Kimozo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYTRZRUJPZy1mTjJMb0VBX3ZEZng4VTE4b2MtNWY1RmJUcXFPX2pYcmIwT3k0SkpGYklwVTZKMER4V2VJNVpkdmZQbUltaTdqRk1KNkx6Zm1TZHJZSDlHWWppRU9qRlRrZ0JEQmJ6QWF0SzA1R2ZfVWlMRm0tb0swaHZkdUJQMlRDZ20wYWdULXFwQ2NDOVBpYmVCdWtkclM5ZmlqbFhzUVFPMHRUSHRVZ3lXU0lCcDdw?oc=5","date":"2019-09-20","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019 - European Medici","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}